| Title |
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
|
|---|---|
| Published in |
Blood Cancer Journal, February 2021
|
| DOI | 10.1038/s41408-021-00430-6 |
| Pubmed ID | |
| Authors |
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis |
Twitter Demographics
The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 8% |
| United States | 1 | 8% |
| Norway | 1 | 8% |
| Unknown | 10 | 77% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 77% |
| Science communicators (journalists, bloggers, editors) | 2 | 15% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 18% |
| Researcher | 6 | 12% |
| Student > Bachelor | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Professor | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 21 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 34% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Immunology and Microbiology | 3 | 6% |
| Business, Management and Accounting | 1 | 2% |
| Arts and Humanities | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 21 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 376. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2023.
All research outputs
#75,478
of 23,940,793 outputs
Outputs from Blood Cancer Journal
#4
of 1,168 outputs
Outputs of similar age
#2,443
of 423,835 outputs
Outputs of similar age from Blood Cancer Journal
#2
of 58 outputs
Altmetric has tracked 23,940,793 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,168 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,835 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.